- Home
- ASC vs KALV Comparison
ASC vs KALV Comparison
Compare ASC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASC | KALV |
|---|---|---|
| Founded | 2010 | N/A |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.4M | 551.2M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASC | KALV |
|---|---|---|
| Price | $10.54 | $16.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $13.67 | ★ $27.17 |
| AVG Volume (30 Days) | 529.3K | ★ 1.4M |
| Earning Date | 02-12-2026 | 11-10-2025 |
| Dividend Yield | ★ 8.97% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $309,326,000.00 | $1,426,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $204.16 |
| P/E Ratio | $13.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.32 | $7.30 |
| 52 Week High | $13.85 | $17.30 |
Technical Indicators
Market Signals| Indicator | ASC | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 28.74 | 59.40 |
| Support Level | $10.59 | $14.83 |
| Resistance Level | $10.90 | $16.30 |
| Average True Range (ATR) | 0.24 | 0.86 |
| MACD | -0.03 | -0.15 |
| Stochastic Oscillator | 16.51 | 56.54 |
Price Performance
Historical ComparisonAbout ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.